Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 1;65(1):59-67.
doi: 10.1097/IIO.0000000000000549. Epub 2024 Dec 23.

Retinal Microstructural and Microvascular Changes in Alzheimer Disease: A Review

Affiliations
Review

Retinal Microstructural and Microvascular Changes in Alzheimer Disease: A Review

Marco Antonio Olivares Ordoñez et al. Int Ophthalmol Clin. .

Abstract

"The eyes are a window to the brain," prompting the investigation of whether retinal biomarkers can indicate Alzheimer disease (AD) and cognitive impairment. AD is a neurodegenerative condition with a lengthy preclinical phase where pathologic changes in the central nervous system (CNS) occur before clinical symptoms. Mild cognitive impairment (MCI) often precedes AD. As part of the CNS, the retina exhibits similar pathologic changes related to AD as those seen in the brains of patients with MCI. Noninvasive imaging technologies such as optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) allow high-resolution visualization of the retina, providing an opportunity to screen and monitor AD noninvasively. In this review, we summarize the relationship between AD and retinal pathology detected by OCT and OCTA. The most common findings in patients with AD include peripapillary retinal nerve fiber layer thinning, decreased macular thickness, an enlarged foveal avascular zone, and decreased vascular densities in the superficial and deep capillary plexuses. These retinal changes correlate with magnetic resonance imaging (MRI) findings of cerebral atrophy, positron emission tomography (PET) findings of increased amyloid load, and neuropsychological testing results suggesting cognitive dysfunction. We conclude that retinal microstructural and microvascular abnormalities may serve as biomarkers for the early detection and clinical monitoring of AD and as tools for evaluating potential treatment effects. Future studies should focus on standardizing protocols for in vivo ophthalmic imaging to measure retinal pathology in AD and MCI.

PubMed Disclaimer

Conflict of interest statement

G.Y. is a consultant for Zeiss (and other companies). The remaining authors declare that they have no conflicts of interest to disclose.

Figures

FIGURE 1.
FIGURE 1.
Tau and amyloid pathology in Alzheimer disease.
FIGURE 2.
FIGURE 2.
OCTA images of the superficial capillary plexus layer comparing the FAZ of a patient with AD to the FAZ of normal control. FAZ enlargement is present in the AD patient.61 AD indicates Alzheimer disease; FAZ, foveal avascular zone; OCTA, optical coherence tomography angiography.

Similar articles

Cited by

References

    1. De-Paula VJ, Radanovic M, Diniz BS, et al. Alzheimer’s disease. Subcell Biochem. 2012;65:329–352. - PubMed
    1. Breijyeh Z, Karaman R. Comprehensive review on Alzheimer’s disease: causes and treatment. Molecules. 2020;25:5789. - PMC - PubMed
    1. Jia J, Wei C, Chen S, et al. The cost of Alzheimer’s disease in China and re-estimation of costs worldwide. Alzheimers Dement. 2018;14:483–491. - PubMed
    1. Colligris P, Perez de Lara MJ, Colligris B, et al. Ocular manifestations of Alzheimer’s and other neurodegenerative diseases: the prospect of the eye as a tool for the early diagnosis of Alzheimer’s disease. J Ophthalmol. 2018;2018:8538573. - PMC - PubMed
    1. Saint-Aubert L, Lemoine L, Chiotis K, et al. Tau PET imaging: present and future directions. Mol Neurodegener. 2017;12:19. - PMC - PubMed

MeSH terms